Government-Owned Inventions; Availability for Licensing, 4501-4502 [2019-02443]

Download as PDF Federal Register / Vol. 84, No. 32 / Friday, February 15, 2019 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings khammond on DSKBBV9HB2PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Biological Chemistry, Biophysics and Assay Development. Date: March 6–7, 2019. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Vonda K. Smith, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6188, MSC 7892, Bethesda, MD 20892, 301–435– 1789, smithvo@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Genomics and Animal/Biological Resource Facilities. Date: March 8, 2019. Time: 2:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Luis Dettin, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2208, Bethesda, MD 20892, 301 451 1327, dettinle@ csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Continuous Submission Applications. Date: March 13, 2019. Time: 12:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Baljit S. Moonga, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4214, MSC 7806, Bethesda, MD 20892, 301–435– 1777, moongabs@mail.nih.gov. VerDate Sep<11>2014 19:41 Feb 14, 2019 Jkt 247001 Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Medical Imaging. Date: March 14–15, 2019. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Holiday Inn Bayside, 4875 North Harbor Drive, San Diego, CA 92106. Contact Person: Leonid V. Tsap, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5128, MSC 7854, Bethesda, MD 20892, (301) 435– 2507, tsapl@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Orthopedic, Skeletal Muscle and Oral Sciences. Date: March 14, 2019. Time: 8:30 a.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Place: Sheraton Washington North Hotel, 4095 Powder Mill Road, Beltsville, MD 20705. Contact Person: Aftab A. Ansari, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4108, MSC 7814, Bethesda, MD 20892, 301–237– 9931, ansaria@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Musculoskeletal, Oral, Skin, Rheumatology and Rehabilitation Sciences AREA (R15) Review. Date: March 15, 2019. Time: 8:30 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: Sheraton College Park North Hotel, 4095 Powder Mill Road, Beltsville, MD 20705. Contact Person: Aftab A. Ansari, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4108, MSC 7814, Bethesda, MD 20892, 301–237– 9931, ansaria@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Rheumatology and Dermatology. Date: March 15, 2019. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Rajiv Kumar, Ph.D., Chief, MOSS IRG, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4216, MSC 7802, Bethesda, MD 20892, 301–435–1212, kumarra@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) PO 00000 Frm 00070 Fmt 4703 Sfmt 4703 4501 Dated: February 9, 2019. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–02404 Filed 2–14–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. to achieve expeditious commercialization of results of federally-funded research and development. SUMMARY: FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892–2479; telephone: 301–402–5579. A signed Confidential Disclosure Agreement may be required to receive any unpublished information. SUPPLEMENTARY INFORMATION: Technology description follows. Adeno-Associated Viruses In Inner-Ear Therapeutics Available for licensing and commercial develop are intellectual property rights associated with adenoassociated viral vector (AAV) mediated inner-ear gene therapy can prevent and reverse hair cell damage to improve auditory function. Hearing loss is associated with age or trauma induced inner ear hair cell damage or hereditary genetic defects in the inner ear development. The delivery of functional copies of mutated or functionally impaired genes can restore hearing. An effective gene therapy requires a powerful delivery vehicle such as a viral vector with high infection efficiency to the inner ear cells. The inventors identified the recombinant AAV2.7m8 virus with modified capsid protein with a high viral vector efficiency for delivering genetic therapeutic payloads to multiple cell types of mammalian inner ear. E:\FR\FM\15FEN1.SGM 15FEN1 4502 Federal Register / Vol. 84, No. 32 / Friday, February 15, 2019 / Notices Potential Commercial Applications —Promising gene therapy vector for the treatment of hearing loss and dizziness. — AAV2.7m8 can be used for human inner ear gene therapy for various diseases of the ear. Development Stage In vivo data in mice available. Inventors: Wade Chien (NIDCD) and Jean Bennett (UPenn). Intellectual Property: HHS Reference No. E–004–2019–0; U.S. Provisional Patent Application No. 62/784,306 filed December 21, 2018. Licensing Contact: Michael Shmilovich, Esq, CLP; 301–435–5019; shmilovm@mail.nih.gov. Dated: February 5, 2019. Michael A. Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. [FR Doc. 2019–02443 Filed 2–14–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health khammond on DSKBBV9HB2PROD with NOTICES National Institute of Environmental Health Sciences; Notice of Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of meetings of the National Advisory Environmental Health Sciences Council. The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Environmental Health Sciences Council. Date: June 4–5, 2019. VerDate Sep<11>2014 19:41 Feb 14, 2019 Jkt 247001 Closed: June 4, 2019, 8:30 a.m. to 10:45 a.m. Agenda: To review and evaluate grant applications. Place: Nat. Inst. of Environmental Health Sciences, Building 101, Rodbell Auditorium, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709. Open: June 4, 2019, 11:00 a.m. to 5:00 p.m. Agenda: Discussion of program policies and issues. Place: Nat. Inst. of Environmental Health Sciences, Building 101, Rodbell Auditorium, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709. Open: June 5, 2019, 8:30 a.m. to 12:00 p.m. Agenda: Discussion of program policies and issues. Place: Nat. Inst. of Environmental Health Sciences, Building 101, Rodbell Auditorium, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709. Contact Person: Gwen W. Collman, Ph.D., Director, Division of Extramural Research & Training, National Institutes of Health, Nat. Inst. of Environmental Health Sciences, 615 Davis Dr., KEY615/3112, Research Triangle Park, NC 27709, (984) 287–3249, collman@ niehs.nih.gov. Name of Committee: National Advisory Environmental Health Sciences Council. Date: September 10–11, 2019. Closed: September 10, 2019, 8:30 a.m. to 10:45 a.m. Agenda: To review and evaluate grant applications. Place: NIEHS/National Institutes of Health, Building, U.S. Environmental Protection Agency, Conference Room 111, 109 TW Alexander Drive, Research Triangle Park, NC 27709. Open: September 10, 2019, 11:00 a.m. to 5:00 p.m. Agenda: Discussion of program policies and issues. Place: NIEHS/National Institutes of Health, Building, U.S. Environmental Protection Agency, Conference Room 111, 109 TW Alexander Drive, Research Triangle Park, NC 27709. Open: September 11, 2019, 8:30 a.m. to 12:00 p.m. Agenda: Discussion of program policies and issues. Place: NIEHS/National Institutes of Health, Building, U.S. Environmental Protection Agency, Conference Room 111, 109 TW Alexander Drive, Research Triangle Park, NC 27709. Contact Person: Gwen W. Collman, Ph.D., Director, Division of Extramural Research & Training, National Institutes of Health, Nat. Inst. of Environmental Health Sciences, 615 Davis Dr., KEY615/3112, Research Triangle Park, NC 27709 (984) 287–3249, collman@ niehs.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: https:// www.niehs.nih.gov/about/boards/naehsc/ PO 00000 Frm 00071 Fmt 4703 Sfmt 4703 index.cfm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS) Dated: February 11, 2019. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–02430 Filed 2–14–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Library of Medicine Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Literature Selection Technical Review Committee. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The portions of the meeting devoted to the review and evaluation of journals for potential indexing by the National Library of Medicine will be closed to the public in accordance with the provisions set forth in section 552b(c)(9)(B), Title 5 U.S.C., as amended. Premature disclosure of the titles of the journals as potential titles to be indexed by the National Library of Medicine, the discussions, and the presence of individuals associated with these publications could significantly frustrate the review and evaluation of individual journals. Name of Committee: Literature Selection Technical Review Committee. Date: October 24–25, 2019. Open: October 24, 2019, 8:30 a.m. to 10:45 a.m. Agenda: Administrative. Place: National Library of Medicine, Building 38, 2nd Floor, The Lindberg Room, 8600 Rockville Pike, Bethesda, MD 20894. E:\FR\FM\15FEN1.SGM 15FEN1

Agencies

[Federal Register Volume 84, Number 32 (Friday, February 15, 2019)]
[Notices]
[Pages 4501-4502]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-02443]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. to achieve 
expeditious commercialization of results of federally-funded research 
and development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; telephone: 301-402-5579. A signed Confidential 
Disclosure Agreement may be required to receive any unpublished 
information.

SUPPLEMENTARY INFORMATION: Technology description follows.

Adeno-Associated Viruses In Inner-Ear Therapeutics

    Available for licensing and commercial develop are intellectual 
property rights associated with adeno-associated viral vector (AAV) 
mediated inner-ear gene therapy can prevent and reverse hair cell 
damage to improve auditory function. Hearing loss is associated with 
age or trauma induced inner ear hair cell damage or hereditary genetic 
defects in the inner ear development. The delivery of functional copies 
of mutated or functionally impaired genes can restore hearing. An 
effective gene therapy requires a powerful delivery vehicle such as a 
viral vector with high infection efficiency to the inner ear cells. The 
inventors identified the recombinant AAV2.7m8 virus with modified 
capsid protein with a high viral vector efficiency for delivering 
genetic therapeutic payloads to multiple cell types of mammalian inner 
ear.

[[Page 4502]]

Potential Commercial Applications

    --Promising gene therapy vector for the treatment of hearing loss 
and dizziness.
    -- AAV2.7m8 can be used for human inner ear gene therapy for 
various diseases of the ear.

Development Stage

    In vivo data in mice available.
    Inventors: Wade Chien (NIDCD) and Jean Bennett (UPenn).
    Intellectual Property: HHS Reference No. E-004-2019-0; U.S. 
Provisional Patent Application No. 62/784,306 filed December 21, 2018.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
shmilovm@mail.nih.gov.

    Dated: February 5, 2019.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2019-02443 Filed 2-14-19; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.